Sample Pro briefing
Sample briefing: how to read an FDA approval
A free, public sample of a proposed educational format for ClinicalInvestor Pro briefings, worked through one historical FDA decision: the June 18, 2025 approval of YEZTUGO (lenacapavir) for HIV pre-exposure prophylaxis.
- Type
- Historical case study, not a live catalyst
- Facts as of
- (the approval date). Nothing later is covered.
- Sources
- Three FDA documents, read as indexed excerpts. See sources
- Authorship
- AI-assisted draft, not individually reviewed by a human editor
How to read this briefing
Every statement below sits under one of three labels, and they should not be mixed up.
- Fact from the FDA record: a statement taken from a named FDA document, with a link to it.
- Editorial interpretation: our reasoning about what a fact does and does not mean. It is opinion and can be wrong.
- Open questions: things this briefing does not answer and a careful reader would go and check.
1. Clinical evidence
Start with what the trials were designed to compare. The design decides what a positive result can and cannot tell you.
Fact from the FDA record
- FDA’s integrated review of the application describes two Phase 3 trials, PURPOSE 1 and PURPOSE 2. Source: FDA integrated review, NDA 220018
- The review describes the primary comparison in those trials as HIV incidence in the trial measured against a background HIV incidence. Source: FDA integrated review, NDA 220018
Editorial interpretation
A comparison against background incidence is a different design from a placebo-controlled trial. It asks how many infections occurred compared with how many would have been expected without prevention, so the estimate of the expected rate is itself part of the evidence. A reader should understand how that estimate was built before leaning on the headline result.
This sample reports no efficacy figures. We worked from indexed excerpts of the FDA documents, not the full review, and a number quoted from an excerpt without its population, analysis set, and confidence interval is easy to misread.
Open questions this briefing does not answer
- How was the background incidence estimated, and how sensitive is the result to that estimate?
- Which populations did each trial enroll, and does the approved use reach beyond them?
- What did the review say about safety findings and discontinuations?
- Were there active-comparator arms, and what role did they play in the analysis?
2. The regulator’s decision
An approval is a specific decision about a specific use. The wording matters more than the headline.
Fact from the FDA record
- FDA’s Drugs@FDA database lists NDA 220018 as YEZTUGO (lenacapavir), with Gilead Sciences as the applicant and an original approval date of June 18, 2025. Source: Drugs@FDA record for NDA 220018
- The approval letter describes the use as pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk of HIV-1 acquisition. Source: FDA approval letter, NDA 220018 (PDF)
Editorial interpretation
The approved use is bounded in three ways a reader can see in the letter’s wording: the route of acquisition, the age groups, and a weight floor. Those bounds define who the product can be promoted for. They are the starting point for any estimate of how many people the approval covers, and this sample has not made or sourced such an estimate.
An approval tells you FDA judged the application to meet its standard for that use on that date. It says nothing about whether prescribers will choose the product, whether insurers will pay for it, or what happens to the label later.
Open questions this briefing does not answer
- What does the current label say? Labels change after approval, and this page describes only the approval-date record.
- Did the approval carry postmarketing requirements or commitments, and what are their timelines?
- What is the regulatory status outside the United States? This case covers the FDA decision only.
3. Commercial questions
The questions here are usually answered from company filings, payer policies, and prescription data. None of those were consulted for this sample.
Fact from the FDA record
This section contains no sourced facts. This sample has not verified price, insurance coverage, uptake, or company financials, and we have not added any from memory.
Editorial interpretation
Clinical and regulatory success does not establish commercial success. Between an approval and a shareholder’s return sit at least four separate steps, and each one can fail on its own.
Adoption: clinicians and patients have to choose the product over the alternatives they already use, and clinics have to be able to deliver it.
Reimbursement: payers decide whether to cover it, for whom, and with what paperwork. A covered product with heavy prior-authorization requirements can sell far below its approved population.
Profitability: revenue has to exceed manufacturing, distribution, and selling costs, and for a large company one product may be a small part of the total.
Security returns: a share price reflects what investors already expected. An approval the market had fully anticipated can leave the price unchanged or lower, so a correct read of the science does not by itself tell you anything about returns.
Open questions this briefing does not answer
- How are payers covering the product, and with what restrictions?
- How does its price and access compare with other prevention options available to the same patients?
- What does delivery require of clinics, and does that limit where it can be offered?
- Do people who start stay on it?
- How material is this one product to the applicant’s total revenue, according to its own SEC filings?
4. Limitations of this sample
- The facts in sections 1 and 2 rest on indexed excerpts of the FDA documents linked below. The full PDFs were not read in preparing this sample, and section 3 contains no sourced facts. Check the wording against the sources yourself before relying on any of it.
- It is historical. It describes the record as of the approval on June 18, 2025 and nothing later: no label changes, no sales, no later trials, no later regulatory actions.
- It gives no efficacy percentages, no dosing or administration information, and no description of the current label.
- It gives no share price, valuation, return, forecast, or upcoming catalyst, and it does not say whether any security is worth buying, holding, or selling.
- It was drafted with AI assistance and has not been individually reviewed by a human editor. No editorial sign-off is claimed.
- It is a sample of a proposed educational format, not a briefing that was delivered to a customer. It is not a complete analysis of this product or this company.
Sources
All three are public FDA documents. The links may be unavailable at times, and this sample relies on indexed excerpts of these documents, not a review of the full PDFs.
- Drugs@FDA record for NDA 220018Used for: Product name, applicant, and original approval date.https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?ApplNo=220018&event=overview.process
- FDA approval letter, NDA 220018 (PDF)Used for: The approved use as worded at approval.https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/220018Orig1s000ltr.pdf
- FDA integrated review, NDA 220018Used for: The Phase 3 trials and the type of primary comparison.https://www.fda.gov/media/189432/download
Explore Pro plans
This page is a sample of a proposed format, not a delivered customer briefing. ClinicalInvestor Pro is $29/month or $249/year. Plan details and checkout are on the pricing page. The one-off catalyst memo is a separate product with its own price.
Not investment advice and not medical advice. This sample is general education about how to read public regulatory documents. It contains no recommendation to buy, sell, or hold any security, no price target, and no personal advice. See our disclosures.